Compare Nike Inc (NKE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nike Inc vs Pfizer Inc — how do they compare? Nike Inc trades at $34.7 (market cap $51.60B), while Pfizer Inc trades at $28.24 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 3.1× Nike Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Nike Inc for 155 Days and Pfizer Inc for 158 Days on average.
| NKE | PFE | |
|---|---|---|
Market Cap | $51.60B | $158.56B |
Volume | 43,506,062 | 44,138,282 |
Sector | Consumer Cyclical | Health |
52-Week High | $69.68 | $29.02 |
52-Week Low | $33.87 | $23.67 |
Typical Hold Time | 155 Days | 158 Days |
Enterprise Value | $54.30B | $210.06B |
Dividend Yield | 4.72% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nike's stock trades at $34.36, down 0.72% with a bearish technical outlook. The company reported $46.31B in revenue for 2025 with a 6.74% net margin, though earnings have beaten expectations in recent quarters. Analyst consensus remains positive with a $36.98 price target, while recent news highlights challenges in China and inventory management.
Nike faces near-term headwinds from slowing revenue growth and margin pressure, but strong brand positioning and consistent earnings beats provide upside potential. Key risks include consumer demand weakness and competitive pressures, while institutional sentiment remains cautiously optimistic for a turnaround.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nike Inc
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
